Orally active quinazolinone-based ghrelin receptor antagonists reduced food intake and improved glucose tolerance in animal models, advancing toward clinical development for combined diabetes and obesity treatment.
Key findingQuinazolinone ghrelin receptor antagonists showed oral bioavailability, reduced food intake, and improved glucose tolerance in animal models — positio
What the researchers found
Quinazolinone ghrelin receptor antagonists showed oral bioavailability, reduced food intake, and improved glucose tolerance in animal models — positioning orally active ghrelin blockade as a dual-mechanism drug approach for treating both diabetes and obesity simultaneously.
Why it matters
Relevant for ghrp, weight-loss, diabetes.
How the study worked
animal-study study on ghrp, weight-loss.
What this study cannot tell us
See abstract.
How to read the evidence
moderate evidence.
When this study was published
Published in 2007.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
- Clinical translation to evaluate.
Common questions
What was studied?
What was found?
Read the original research
Quinazolinone derivatives as orally available ghrelin receptor antagonists for the treatment of diabetes and obesity.
Journal of medicinal chemistry, 50(21), 5202-16
Citation
Rudolph, Joachim; Esler, William P; O'connor, Stephen; Coish, Philip D G; Wickens, Philip L; Brands, Michael; Bierer, Donald E; Bloomquist, Brian T; Bondar, Georgiy; Chen, Libing; Chuang, Chih-Yuan; Claus, Thomas H; Fathi, Zahra; Fu, Wenlang; Khire, Uday R; Kristie, James A; Liu, Xiao-Gao; Lowe, Derek B; McClure, Andrea C; Michels, Martin; Ortiz, Astrid A; Ramsden, Philip D; Schoenleber, Robert W; Shelekhin, Tatiana E; Vakalopoulos, Alexandros; Tang, Weifeng; Wang, Lei; Yi, Lin; Gardell, Stephen J; Livingston, James N; Sweet, Laurel J; Bullock, William H. (2007). Quinazolinone derivatives as orally available ghrelin receptor antagonists for the treatment of diabetes and obesity.. Journal of medicinal chemistry, 50(21), 5202-16.